{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:47:45Z","timestamp":1784958465538,"version":"3.55.0"},"reference-count":44,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Over the last decades, different quadrivalent antimeningococcal vaccine formulations (diphteria toxoid conjugate, MenACWY-D; tetanus toxoid conjugate, MenACWY-TT; CRM197 protein conjugate, MenACWY-CRM) have been developed. However, their availability varies, both in terms of authorized formulations and of inclusion in vaccination schedules. Furthermore, several countries include only the monovalent meningococcal C (MenC) vaccine in their immunization programmes. Finally, there is currently no updated systematic review that directly compares the MenACWY formulations. Thus, we summarized the evidence on efficacy and safety through four parallel, independent systematic literature reviews with meta-analysis which included randomized controlled trials comparing the abovementioned vaccines. A total of 16 studies have been included. In terms of efficacy, MenACWY-TT outperformed MenACWY-D and MenACWY-CRM for A, W-135, and Y serogroups, while no significant difference was found for serogroup C. Furthermore, we did not find significant differences in efficacy between MenC and MenACWY-TT. Regarding the safety, we were able to perform a quantitative analysis only between MenACWY-TT and MenC, finding no significant differences. Similarly, among the different MenACWY formulations no relevant differences were identified. These findings suggest that MenACWY-TT could be preferable to other formulations to improve current vaccination programs and to better develop future immunization policies.<\/jats:p>","DOI":"10.3390\/vaccines11010178","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T02:29:55Z","timestamp":1673836195000},"page":"178","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-117X","authenticated-orcid":false,"given":"Andrea","family":"Conti","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Broglia","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-4156","authenticated-orcid":false,"given":"Chiara","family":"Sacchi","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Risi","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-436X","authenticated-orcid":false,"given":"Francesco","family":"Barone-Adesi","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-7198","authenticated-orcid":false,"given":"Massimiliano","family":"Panella","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: Clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","article-title":"Costs of Invasive Meningococcal Disease: A Global Systematic Review","volume":"36","author":"Wang","year":"2018","journal-title":"PharmacoEconomics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2014.10.006","article-title":"Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis","volume":"92","author":"Pellegrino","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_5","unstructured":"World Health Organization (2011). Meningococcal vaccines: WHO position paper, November 2011. Relev. Epidemiol. Hebd., 86, 521\u2013539."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J. Adolesc. Health"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pizza, M., Bekkat-Berkani, R., and Rappuoli, R. (2020). Vaccines against Meningococcal Diseases. Microorganisms, 8.","DOI":"10.3390\/microorganisms8101521"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: An analysis of surveillance data","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tin Tin Htar, M., Jackson, S., Balmer, P., Serra, L.C., Vyse, A., Slack, M., Riera-Montes, M., Swerdlow, D.L., and Findlow, J. (2020). Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-09946-1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"21188","DOI":"10.2807\/1560-7917.ES2015.20.28.21188","article-title":"Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015","volume":"20","author":"Campbell","year":"2015","journal-title":"Eurosurveillance"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","article-title":"Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations","volume":"116","author":"Taha","year":"2022","journal-title":"Pathog. Glob. Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4161\/hv.27739","article-title":"Review of meningococcal vaccines with updates on immunization in adults","volume":"10","author":"Zahlanie","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","first-page":"89","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"B117","DOI":"10.1016\/j.vaccine.2009.04.066","article-title":"Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease","volume":"27","author":"Granoff","year":"2009","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection?serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/INF.0000000000002832","article-title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Na\u00efve Children 2\u20139 Years of Age: A Phase III, Randomized Study","volume":"39","author":"Baccarini","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2016.05.009","article-title":"Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers","volume":"34","author":"Bona","year":"2016","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","article-title":"A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States","volume":"38","author":"Chang","year":"2020","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","article-title":"Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study","volume":"38","author":"Dhingra","year":"2020","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jpids\/pit058","article-title":"Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10\u201325 Years of Age","volume":"3","author":"Halperin","year":"2014","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2\u201310-year-old children: Results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2052657","DOI":"10.1080\/21645515.2022.2052657","article-title":"Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-na\u00efve toddlers: A randomised, controlled trial","volume":"18","author":"Knuf","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1016\/j.ijid.2010.03.017","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America","volume":"14","author":"Stamboulian","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles\u2013mumps\u2013rubella\u2013varicella vaccine during the second year of life: An open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_35","unstructured":"World Health Organization (2016). Global Manual on Surveillance of Adverse Events Following Immunization, WHO Document Production Services."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJMp1110539","article-title":"The Role of Cost-Effectiveness in U.S. Vaccination Policy","volume":"365","author":"Kim","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2021.1880209","article-title":"Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine","volume":"17","author":"Watle","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hepkema, H., Pouwels, K.B., van der Ende, A., Westra, T.A., and Postma, M.J. (2013). Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065036"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1016\/j.vaccine.2019.07.008","article-title":"Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents","volume":"37","author":"Si","year":"2019","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Delea, T.E., Weycker, D., Atwood, M., Neame, D., Alvarez, F.P., Forget, E., Langley, J.M., and Chit, A. (2017). Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175721"},{"key":"ref_41","unstructured":"(2022, December 15). CDC Vaccine Price List, Available online: https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","volume":"15","author":"Findlow","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jinf.2022.09.001","article-title":"Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB","volume":"85","author":"Fragapane","year":"2022","journal-title":"J. Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S1473-3099(21)00193-6","article-title":"Migration and outbreaks of vaccine-preventable disease in Europe: A systematic review","volume":"21","author":"Deal","year":"2021","journal-title":"Lancet Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/1\/178\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:38Z","timestamp":1760119538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/1\/178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["vaccines11010178"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11010178","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}